PROJECT EXAMPLES
Always delivering insight-generating
customised solutions
ASSET SEARCH & EVALUATION
Situation: A US biotech company experienced a series of unexpected setbacks in their pipeline. To mitigate this, they desired to in-license several assets to fill the gaps
Approach: SCITARIS deployed our systematic asset search methodology which utilizes priority algorithms to filter and prioritize 76k+ biopharma drugs in development world-wide, with the top-ranked candidates analyzed first at a high-level and then by comprehensive deep-dive review
Outcome: The firm presented several candidates to their board and the decision was taken to in-license
DUE DILIGENCE SUPPORT
Situation: A US biotech is highly interested in licensing a Phase IIb asset. After previous high-level reviews, full due diligence has been initiated and timelines are tight with multiple other interested competitors exploring the data room.
Approach: SCITARIS supports both technical as well as commercial Due Diligence in a stuctured, thorough and timely manner. Using our meticulous methodology, we work with the client’s team to ensure all boxes have been ticked and all potential risks are flagged before closing a potential deal.
Outcome: Based on the thorough analysis of the dataroom a significant CMC hurdle and commercial constraints were flagged, which led to rational deprioritization of this opportunity and prioritization of another interesting alternative.
PRECLINICAL DEVELOPMENT STRATEGY
Situation: A mid-sized US biotech historically focused on the infectious disease space experienced a late-stage failure. In consequence, the management changed the company’s strategic focus by in-licensing an early-stage asset targeting an orphan autoimmune disease. The firm is looking to complement the ongoing clinical studies with meaningful preclinical insights into the mode of action.
Approach: SCITARIS helped building various target and mode of action hypotheses for the molecule based on extensive literature research and key opinion leader interviews. Proposals for relevant experiments to test each of these hypotheses were designed and prioritized with the scientific teams, as well as suitable CROs and academic institutions identified to conduct these studies.
Outcome: The company initiated studies SCITARIS recommended and has generated first signals to be presented to investors and at upcoming scientific conferences.
INDICATION SCREEN & DEVELOPMENT STRATEGY
Situation: A mid-size pharma company has a compound which modulates a novel target involved in various disease processes. They want to comprehensively prioritize indications for lead and follow-on development.
Approach: At SCITARIS, we believe that indication selection should be primarily science-driven. Therefore, we used a comprehensive screening approach to prioritize 21k+ indications for fit to the target biology and chosen modality, in addition to taking into account specific company requirements, development and commercial considerations.
Outcome: The company implemented the indication and combination strategy we recommended as the best balance between risk, reward and time to market.
ASSET POSITIONING SUPPORT FOR PARTNERING
Situation: A project team has successfully navigated their asset through early clinical development and is now seeking additional financing or partnering. Focused on de-risking, the team’s mindset is set on the challenges ahead instead of the opportunities. The firm now needs of a pair of capable and fresh eyes to optimize the assets positioning according to the current landscape in order to attract potential partners.
Approach: SCITARIS reviewed all relevant asset information and worked out the key strengths and potential upside opportunities together with the client’s team in an iterative process. Based on these learnings, SCITARIS drafted the storyline and conducted additional supporting analyses to build the confidential presentation, as well as a set of non-confidential materials for partnering discussions.
Outcome: The company used the generated materials for large investor pitches and is currently in a number of ongoing partnering discussions.
